Free Trial
NASDAQ:UBX

Unity Biotechnology (UBX) Stock Price, News & Analysis

Unity Biotechnology logo
$0.90 -0.09 (-9.09%)
Closing price 04:00 PM Eastern
Extended Trading
$0.94 +0.04 (+4.67%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Unity Biotechnology Stock (NASDAQ:UBX)

Key Stats

Today's Range
$0.88
$1.00
50-Day Range
$0.96
$2.38
52-Week Range
$0.89
$3.10
Volume
208,543 shs
Average Volume
115,705 shs
Market Capitalization
$15.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.33
Consensus Rating
Buy

Company Overview

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Remove Ads

Unity Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

UBX MarketRank™: 

Unity Biotechnology scored higher than 78% of companies evaluated by MarketBeat, and ranked 187th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Unity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Unity Biotechnology has only been the subject of 2 research reports in the past 90 days.

  • Read more about Unity Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for Unity Biotechnology are expected to grow in the coming year, from ($1.45) to ($1.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Unity Biotechnology is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Unity Biotechnology is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Unity Biotechnology has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Unity Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    4.16% of the float of Unity Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Unity Biotechnology has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Unity Biotechnology has recently increased by 15.32%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Unity Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Unity Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.16% of the float of Unity Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Unity Biotechnology has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Unity Biotechnology has recently increased by 15.32%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Unity Biotechnology has a news sentiment score of -0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Unity Biotechnology this week, compared to 0 articles on an average week.
  • Search Interest

    Only 4 people have searched for UBX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Unity Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Unity Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,405.00 in company stock.

  • Percentage Held by Insiders

    Only 5.80% of the stock of Unity Biotechnology is held by insiders.

  • Percentage Held by Institutions

    Only 29.49% of the stock of Unity Biotechnology is held by institutions.

  • Read more about Unity Biotechnology's insider trading history.
Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Stock News Headlines

HC Wainwright Has Negative Forecast for UBX FY2026 Earnings
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Unity Biotechnology price target lowered to $4 from $6 at Chardan
See More Headlines

UBX Stock Analysis - Frequently Asked Questions

Unity Biotechnology's stock was trading at $0.9764 at the beginning of 2025. Since then, UBX stock has decreased by 6.8% and is now trading at $0.91.
View the best growth stocks for 2025 here
.

Unity Biotechnology, Inc. (NASDAQ:UBX) released its quarterly earnings data on Monday, November, 4th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.02.

Unity Biotechnology shares reverse split on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Unity Biotechnology (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Unity Biotechnology investors own include Plug Power (PLUG), NVIDIA (NVDA), NIO (NIO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Enovix (ENVX) and Nokia Oyj (NOK).

Company Calendar

Last Earnings
11/04/2024
Today
4/04/2025
Next Earnings (Estimated)
4/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UBX
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.33
High Stock Price Target
$8.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+486.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-39,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$240,000.00
Price / Cash Flow
N/A
Book Value
$1.69 per share
Price / Book
0.54

Miscellaneous

Free Float
15,873,000
Market Cap
$15.35 million
Optionable
Optionable
Beta
1.30
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:UBX) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners